Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • NeoGenomics, Inc. (NEO) Launches Tests For Profiling Of Myelodysplastic Syndrome 0 comments
    Jul 25, 2013 3:08 PM | about stocks: NEO

    NeoGenomics is a leading clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company's testing services include: cytogenetics, morphology studies, anatomic pathology, flow cytometry, immunohistochemistry, fluorescence in-situ hybridization, and molecular genetic testing.

    The company announced today it had validated and introduced a number of clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome (NYSE:MDS). MDS is a complex and hard-to-diagnose disease because of its wide range of clinical behaviors. It is myeloid malignancy characterized by peripheral blood cytopenias. The disease can arise de novo or after therapies for other cancers such as chemo or radiation therapies. It is diagnosed in more than 10,000 people annually in the U.S.

    NeoGenomics' comprehensive MDS testing covers all of the known relevant molecular mutations associated with the disease. The company now provides mutation analysis of the following genes: SF3B1, U2AF1, SRSF2, ZRSR2, RUNX1, EZH2, ASXL1, TET2, TP53, NRAS, CBL, PTPN11, IDH1/2, and ETV6. The genes can be analyzed individually or as a group. NeoGenomics' tests can provide profound insights into the disease and guide physicians in designing the proper personalized therapeutic strategies for each individual patient.

    The new MDS tests mean the company now offers the most extensive menu of molecular testing services focused on cancer in the U.S. The tests are part of NeoGenomics' strategy to become the leading laboratory in the quickly evolving field of molecular pathology. For additional information about NeoGenomics, its new MDS tests, and its entire range of testing services, please visit www.neogenomics.com.

    Please see disclaimer on the MissionIR website
    http://www.missionir.com/disclaimer.html

    Stocks: NEO
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.